BURLINGTON, Mass. - Fractyl Health, Inc. (NASDAQ:GUTS) announced today the appointment of Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy.
Zumdahl previously served as Vice President of Global Health Economics, Market Access, and Government Affairs at Inari Medical, where he led the function through the company’s growth until its acquisition by Stryker for approximately $4.9 billion in February 2025. Most recently, he was President of Commercial Access Partners, advising medical technology companies on go-to-market strategy, health economics, and reimbursement.
Earlier in his career, Zumdahl spent nearly a decade at Novo Nordisk in roles including National Accounts and Government Payers, where he contributed to the company’s Health Economics and Outcomes Research strategy and value-based contracting for GLP-1 therapies. He started his career as a sales representative at GSK.Zumdahl joins Fractyl as the company navigates a challenging period, with shares down 63% year-to-date to trade at $0.81, giving it a market capitalization of $127.9 million. Despite the stock’s recent weakness, the company maintains a current ratio of 4.28, indicating liquid assets exceed short-term obligations.
The appointment comes as Fractyl prepares for the anticipated REMAIN-1 Pivotal Cohort topline readout in early Q4 2026 and a potential De Novo marketing application submission for Revita in late Q4 2026, according to a press release statement. Analysts maintain an optimistic outlook with price targets ranging from $2 to $8, and InvestingPro subscribers can access the company’s comprehensive Pro Research Report for deeper insights into Fractyl’s clinical pipeline and commercial prospects.
Revita is Fractyl’s lead product candidate, designed to remodel the duodenal lining via a one-time, minimally invasive endoscopic procedure. The treatment has received Breakthrough Device designation from the U.S. Food and Drug Administration for weight maintenance in people with obesity who discontinue GLP-1 therapies. Revita is for investigational use only in the United States and is CE marked in the European Union and United Kingdom.
Fractyl Health is a clinical stage metabolic therapeutics company advancing two product candidates targeting obesity and type 2 diabetes: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform. The company is headquartered in Burlington, Massachusetts.
In other recent news, Fractyl Health Inc. reported its first-quarter 2026 earnings, significantly exceeding analysts’ expectations. The company posted an earnings per share (EPS) of -$0.06, compared to the forecasted -$0.25, resulting in a 76% surprise. Despite reporting no revenue, the company’s strategic cost management and progress in clinical trials were highlighted as key factors contributing to this positive outcome. The earnings report reflects investor optimism, as seen in the market’s reaction. These developments indicate Fractyl Health’s ongoing efforts to advance its clinical objectives while maintaining financial discipline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates GUTS alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if GUTS is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?